

**Date: April 02, 2025**

To, The Manager, Listing Department, <b>National Stock Exchange of India Limited,</b> Exchange Plaza, C-1, Block – G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.	To, The Department of Corporate Service, <b>BSE Limited,</b> 1 <sup>st</sup> Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001.
<b>Scrip Code – LINCOLN</b>	<b>Scrip Code – 531633</b>

Dear Sir,

**SUB.: Forwarding Yearly Disclosure under Regulation 31(4) of SEBI (SAST) Regulations, 2011 by the Promoter and Promoter Group along with person acting in concert of the Company for the Financial year ended on 31st March, 2025.**

Please find enclosed here with the yearly disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 as amended, received from the Promoter and Promoters Group of the Company for the year ended on 31st March, 2025 for your kind perusal and records.

Kindly take a note of the same.

Thanking you,

**Yours faithfully,  
For Lincoln Pharmaceuticals Limited,**

\_\_\_\_\_  
**Trusha Shah  
Company Secretary & Compliance Officer**

**Encl. As above**

# **Munjal Mahendrabhai Patel**

**Address:** 37, Sarathi-III, Near Surdhara Circle, Drive-In-Road, Thaltej,  
Ahmedabad – 380059, **Ph. No.:** +91-79-4107-8004,  
**Email ID:** munjal@lincolnpharma.com.

Date: April 02, 2025

To, The Manager, Listing Department, <b>National Stock Exchange of India Limited,</b> Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. <b>SYMBOL – LINCOLN</b>	To, The Department of Corporate Service, <b>BSE Limited,</b> 1 <sup>st</sup> Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001. <b>Scrip Code – 531633</b>
---	--


Dear Sir/Madam,

**Sub: Disclosures under Regulation 31 (4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.**

Pursuant to the provision of the Regulation 31 (4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, it is hereby declared that the Promoter / Promoter Group along with persons acting in concert (PAC) of target company i.e. Lincoln Pharmaceuticals Limited holding 99,69,930 Equity shares of face value Rs. 10/- each as on March 31, 2025 have not made any encumbrance of shares Directly or Indirectly during the Financial Year 2024-2025.

Kindly acknowledge the receipt of the same.

Thanking you,  
Yours Truly,



**Munjal M. Patel**  
**(For and on behalf of Promoter/  
Promoter group and PAC)**

CC:  
To,  
The Chairman, Audit Committee;  
**LINCOLN PHARMACEUTICALS LIMITED**  
CIN: L24230GJ1995PLC024288  
"LINCOLN HOUSE", Behind Satyam Complex,  
Science City Road, Sola, Ahmedabad – 380 060.